SciTech is a clinical stage, biopharmaceutical company that has developed a proprietary nano-delivery system (SciTech Drug Delivery Platform - SDP) to enable intravenous (IV) delivery of water-insoluble drugs. One such challenged drug or active pharmaceutical ingredient (API) is fenretinide, the API in SciTech's lead drug candidate, has been shown in numerous clinical trials to be a relatively safe and effective anticancer therapy with targeted cancer destroying activity. The patented combination of the new SDP and fenretinide has led to SciTech’s first drug candidate, ST-001 nanoFenretinide, that holds the promise of improving and saving many lives.
Intellectual Property: SciTech is the inventor, co-owner and exclusive licensee of U.S. Patent No. 8,709,379 (issued April 29, 2014) titled “Liposomal Nanoparticles and Other Formulations of Fenretinide for Use in Therapy and Drug Delivery”. International patent coverage includes the major global oncology markets: Canada, EU, Australia and New Zealand. SciTech has recently filed a provisional patent titled “Use of Fenretinide Nanoparticles for Immunotherapeutic Cancer Treatment” (U.S. Patent Application No. 62/769,822 November 20, 2018) claiming the immune oncology effects of ST-001 nanoFenretinide.
The Mission of SciTech Development is to rapidly advance the development of meaningful therapeutic agents previously hampered by formulation and delivery hurdles which can now be overcome with SciTech’s proprietary technology. SciTech believes these enhanced agents can have immense value in treating diseases with high unmet clinical need in attractive markets. In the case of fenretinide (ST-001 nanoFenretinide), the company has successfully completed the task of finally delivering on the promise of fenretinide as an anticancer agent.
Earle T. Holsapple III,
President & Co-Founder
Mr. Holsapple has extensive managerial experience spanning many decades in a wide host of industries. He has successfully served as CEO/COO of six profitable midsize industrial or consumer products companies ranging in size from $10M to $100M in sales. He has managed four corporate turnarounds restoring each company to financial health. As an entrepreneur, he has started four new companies ranging in focus from international trade to complex life science startups. From a life science industry perspective, he led the Center for Cancer Economic, Technology Assessment, Innovation & Development (CETAID) for the Karmanos Cancer Institute (KCI) where his team of scientists and clinicians developed numerous new technologies for detecting or treating cancer. SciTech is one of those companies that spun out of CETAID/KCI. In his leadership capacity, he also managed the development and raised the initial funding (~$17.M) for the SoftVue™ technology. SoftVue™ is a novel breast cancer detection product now in massive clinical trials under license with Delphinus Medical Technologies, Inc. Delphinus recently received FDA PMA approval to use SoftVue™ in combination with mammography to better detect breast cancer in women with dense breasts, a potential large market opportunity. Mr. Holsapple also has experience in leading and raising financing to conduct leverage buyouts of some of the above companies. In the case of the startups, he was responsible for raising the capital, from a broad cross section of sources, to finance the businesses. He previously served his country as an air defense officer in the United States Marine Corps rising to the rank of Captain.
Dr. Burns has nearly 40 years of extensive pharmaceutical industry experience that includes R&D, product development, sales & marketing, licensing and M&A. He is the retired President and Chief Operating Officer of Ferndale Pharma Group which comprises companies that specialize in the development, manufacture, marketing, sale and distribution of a wide variety of healthcare products including prescription and over-the counter drug products and medical devices. Dr. Burns was also CEO of Repromedix Corp, a life science company providing advanced testing and advisory services in reproductive medicine. He was instrumental in the divestment of the company to ReproSource, Inc. where he facilitated post acquisition capital raises and supported operational activities. At present, Dr Burns provides consulting and advisory services to start up companies in skin care, reproductive medicine and oncology.
Dr. Parchment is an accomplished pharmacologist and the principal inventor of the SciTech drug delivery technology. He presently directs a multi-laboratory program at the Frederick National Laboratory for Cancer Research where he manages the effort to create innovative approaches for evaluating and developing new drug compounds. He has worked part-time supporting SciTech’s development, patenting and commercialization activities. He brings a wealth of knowledge, in the field of oncology drug development, to bear on SciTech’s behalf. He invented ST-001 while on the faculty of Wayne State University where he was a core leader for the Karmanos Cancer Institute (KCI).
Michael Burns, PhD,
Head of Product
Ralph E. Parchment, PhD,Chief Scientific Advisor & Co-Founder
Mr. Stumpf brings 20+ years of experience as a finance professional in private equity, investment banking, corporate finance, and public accounting. Mr. Stumpf serves on the board of directors of a public diversified holding company as a member on the audit, compensation and nominating committees. Mr. Stumpf is a partner with Storm Lake Capital, a private equity firm that invests in middle market companies. Mr. Stumpf also performs in a finance capacity for several portfolio companies with responsibilities including financial and strategic planning and budgeting, financial reporting and year-end audit and tax filings.
Dr. Scarmoutzos has over 30 years of industrial experience in the biotech, chemistry, healthcare, medical device, pharmaceutical, and related industries. His hands-on industrial experience ranges from Bench Top Scientist to Vice President of R&D to President and CEO. He has founded several companies and is currently a Board Member of several small and emerging companies. Dr. Scarmoutzos received his B.S. cum laude in Chemistry from Boston College, a Ph.D. summa cum laude in Organic Chemistry from the Pennsylvania State University and was a Post-Doctoral Fellow in the Department of Chemistry and Chemical Biology at Harvard University. He has worked extensively with startups and established companies in the areas of entrepreneurship, technology commercialization, business development, marketing, intellectual property development and fund raising. He is an author of numerous peer-reviewed technical and non-technical articles and holds several issued U.S. and International Patents.
Dr. Scarmoutzos continues to serve as a Principal Advisor in the Life Sciences Group at the Larta Institute (Los Angeles Regional Technology Alliance). He was a Principal Advisor in the National Institutes of Health Commercialization Assistance Program (NIH CAP) since its inception in 2004 and continuously through 2020 at which time the program ended. He has held Principal Advisory positions at the National Science Foundation (NSF) and the National Institute of Standards and Technology (NIST). He continues to serve in an advisory capacity to both the private sector and government. He has held adjunct faculty positions at several universities including Augusta University and Paine College. Owing to his academic and commercial experience, Dr. Scarmoutzos has a dual proficiency in both science and business. As such, he has an excellent profile that supports and warrants both scientific product development as well as overarching, long-term commercial objectives.
Attorney, Immix Law Group,
General Counsel, Former CEO of
a startup pharmaceutical tool company. She specializes in business and SEC law.
Louis M. Scarmoutzos, PhD
Chief Operating Officer
Elizabeth H. Kraus,
Christine D. Copple, PhD
Senior Vice-President, Strategy
Dr. Copple brings thirty plus years of international experience in varied biotechnology enterprises as a founder, corporate officer, and board member. Dr. Copple has a Ph.D. in molecular biology from the University of Birmingham, UK with over ten years of bench research experience. Her industry responsibilities have included fund raising and investor relations, business development, operations, cGMP manufacturing build/design, regulatory affairs, human resources, international marketing and sales, corporate communication, legislative liaison, and R&D. Dr Copple is a founder of 2 publicly traded companies - Microfluidics and Neuralstem and ran the seed venture fund of the American Society of Microbiology. She is on the Board of miRecule Inc. and has held positions at Trove Therapeutics and Vimalea Therapeutics, and serves on the Maryland Industrial Partnerships Board and the Washington D.C. ArchAngels Board.
Dr. Moiin is board certified in Dermatology and is a practicing Dermatologist. He maintains affiliations with major medical centers in the Detroit metro area, including Detroit Medical Center, St. John's Hospital, St. Mary's Hospital and William Beaumont Hospital. Dr. Moiin received his bachelor's degree in pharmacology and master's degree in biology from the University of California, Santa Barbara. He received further training in pharmacy at the University of California, San Francisco and awarded his Doctor of Medicine degree from the University of California, Davis.
Ali Moiin, MD
Division Manager, Topical Products
Andrew J. Stumpf
Timothy Kuzel, MD,
Hematologist/Oncologist, Rush University Medical Center
Kenneth Massey, PhD,
Senior Director, Venture Development, WSU; Chairman, MichBio
Michael B. Sporn, MD,
Emeritus Professor of Pharmacology and Toxicology, Emeritus Professor of Medicine, Geisel School of Medicine at Dartmouth
Michael Wang, MD, PhD, MBA,
Chief Strategy Officer, National Foundation for Cancer Research (NFCR); COO, Asian Fund for Cancer Research
William Werkmeister, MBA,
Partner, HRN; Managing Partner, Oncology Impact Partners